Michael Polansky Trains Advanced AI With Near-Living Human Skin Tissue

Michael Polansky is remarkably unassuming for someone operating in a corner of the world known for outsize egos.

Positioned on a leafy patio beside a popular bakery in Mill Valley, approximately fifteen miles north of San Francisco, sits Polansky—an affable figure with wire-rimmed glasses and a youthful appearance softened by hints of silver threading through his dark hair. Despite his easy demeanor, he embodies the quiet intensity of a young academic.

As co-founder of Outer Biosciences and the longtime partner of Lady Gaga, Polansky navigates two vibrant identities simultaneously. The duo frequently traverses the glamorous circuits of the entertainment world while concurrently steering a biotechnology venture dedicated to maintaining human tissue vitality outside the living body—a odyssey sustained for more than a month with limited external awareness.

His origins trace to Minnesota, where he earned his degrees at Harvard—studying applied mathematics and computer science, graduating in 2006. He subsequently spent three years at Bridgewater Associates, describing the experience as unique yet generally une exciting daily. That stint paved the way for a pivotal chapter in his career: a chance encounter with Sean Parker during a 2009 wedding, leading to a move west and eventual departure from Bankruptcy to launch his own trajectory in venture capital and entrepreneurship.

Upon joining Founders Fund under its original quadrupartite leadership—Peter Thiel, Sean Parker, Luke Nosek, and Ken Howery—Polansky quickly established himself as a central figure. Later, when Parker established his personal family office after liquidity events, Polansky oversaw that operation, managing investments and philanthropic initiatives, including instrumental contributions to the Parker Institute for Cancer Immunotherapy before his focus shifted toward medical applications during pandemic disruptions.

The partnership with Lady Gaga deepened beyond romance into meaningful collaboration. Met jointly in late 2019 through introductions arranged by her mother, the pair quickly forged mutual respect and shared purpose. Their combined enterprise now orchestrates complex logistics—for instance, mounting multi-aircraft operations for gala performances across continents—and has nurtured complementary ventures tied to the founder’s entrepreneurial spirit.

Beyond healthcare outreach, Polansky cultivated a robust business portfolio that anchors much of his public profile. The Haus Labs cosmetics brand, born from Gaga’s vision and operationalized through his guidance, exemplifies his cross-disciplinary ambitions. Together they oversee collaborations between Outer Biosciences and house labs, with the latter drawing on scientific expertise aligned with the company’s tissue preservation capabilities.

This innovative approach addresses a critical gap in biomedical research: the inability to conduct real-time experiments on sentient human tissue within controlled laboratory settings. Outer Biosciences sources remaining viable skin grafts—recovered from post-surgical discard—through carefully vetted nonprofit and commercial biobanks under Institutional Review Board oversight and documented donor consent, ensuring rigorous ethical compliance across National Disease Research Interchange channels and the Cooperative Human Tissue Network.

The procurement strategy emphasizes cost-effective sustainability over immediate acquisition. Rather than purchasing tissue outright, the organization pays suppliers on a fee-for-service basis while investing approximately two years into establishing pipelines capable of processing living samples within hours following surgical removal. Protocols guarantee thorough de-identification prior to entry, and proprietary nutrient delivery systems extend tissue lifespan far beyond conventional benchmarks.

Current tissue viability exceeds forty-five days according to Polansky, enabling researchers to observe collagen remodeling, pigmentation shifts, and barrier maturation unfolding over extended periods. These temporal windows permit longitudinal studies of ultraviolet-induced damage and subsequent biological recovery, providing insights unattainable through standard in vitro approaches limited to short-term outcomes.

The institutional knowledge base forms the backbone of their technological advancement. Each successful prediction fuels iterative refinement: AI models anticipate effective organic compounds, those substances undergo live tissue evaluation, and resulting performance data re-enriches the algorithmic framework. This self-consistent loop accelerated project throughput dramatically, shifting production cycles from eighteen-month hiatuses of brute-force literature mining to continuous weekly generation of novel candidates.

Early efforts relying on extensive scientific databases and public-licensed natural compounds yielded preliminary findings but lacked scalability. Modern iterations leverage machine intelligence to process the minuscule global database of potential skin-active molecules, creating pathways previously invisible to traditional researchers seeking efficiencies far faster than pharmaceutical development paradigms allow.

Commercialization enters gradually as Outer Biosciences explores downstream diversification strategies. Current priorities involve licensing validated ingredients to independent formulators rather than brand construction. Several of their top-performing candidates already demonstrate feasibility in emerging product formulations slated for dermatological markets. Simultaneously, strategic partnerships with pharmaceutical developers examine transdermic irritation mechanisms, while consumer beauty sectors evaluate whether peer-developed datasets match proprietary methodologies.

Financial momentum supports continued expansion. The venture has secured approximately twenty-three million dollars in financing from investors including Wing Ventures, Initialized Capital, and Hawktail. Operating primarily out of Cambridge, Massachusetts with nineteen employees—each positioned near neighboring institutions—the organization focuses both capital-raising activities and translational scaling endeavors.

Recent emphasis on visibility marks Polansky’s decision to engage openly following prolonged secrecy. He attributes increased confidence in demonstrated effectiveness and growing public interest to accumulated empirical data. Accessibility represents a deliberate strategy: moving from confidential research to broader societal contribution as clinical validation strengthens.

The competitive landscape remains richly contested despite these advantages. Vivodyne, Philadelphia-based, recently raised eighty million dollars overall on a substantial series—demonstrating investor appetite for integrated live-tissue oncology platforms. Other participants pursue parallel trajectories involving microphysiological systems, organ chips, and alternative computational frameworks targeting preclinical screening gaps that could benefit both automotive automotive auto and digital health sectors.

Notwithstanding competitors, Polansky emphasizes intrinsic differentiation rooted in tangible advantages rather than mere arrogance. Biological material repositories of uncontrollable variability offer resistance to rapid disruption that would otherwise undermine technology-intensive firms grounded solely in big-data inference. Moreover, the absence of any comparable open-source “biology web”—no public repository containing comprehensive cellular and systemic dynamics—to harvest constitutes both a defensive moat and a pragmatic resource constraint that shapes organizational priorities toward foundational discovery rather than speed-to-market optimization.

Furthermore, the nascent nature of the tissue dataset itself introduces distinct challenges for intellectual property positioning and market valuation. While precise quantification varies, the space encompasses fewer than two hundred actively researched active components—far fewer than the thousands of approved skincare ingredients traditionally classified by regulatory agencies. Even accounting for ancillary cosmetic additives under scientific scrutiny, the frontier warrants considerable exploration.

As an ingredient company rather than a drug manufacturer, Outer Biosciences avoids direct therapeutic regulation. Instead, discovery proceeds through industrial nomenclature establishment followed by systematic safety evaluation adhering to OECD tripartite directives maintained by international bodies. Collaborative consortia distribute ownership responsibilities, with licensed entities responsible for commercialization while underlying research teams refine formulation readiness.

Looking ahead, the organization prioritizes transitioning promising compounds into scalable products through methodical formulation, manufacturing scalability, and supply chain integration. Manual teams continue guiding the conversion of novel agents into consumer-grade serums or creams, bridging investigative gains with accessible retail formats. Near-term commercialization appears imminent given preliminary efficacy signals demonstrating relevance to contemporary dermatological needs.

Source link